Supplemental Digital Content is available in the text. While hypertension and inflammation are physiologically inter-related, the effect of therapies that specifically target inflammation on blood pressure is uncertain. The recent CANTOS (Canakinumab Anti-inflammatory Thrombosis Outcomes Study) afforded the opportunity to test whether IL (interleukin)-1β inhibition would reduce blood pressure, prevent incident hypertension, and modify relationships between hypertension and cardiovascular events. CANTOS randomized 10 061 patients with prior myocardial infarction and hsCRP (high sensitivity C-reactive protein) ≥2 mg/L to canakinumab 50 mg, 150 mg, 300 mg, or placebo. A total of 9549 trial participants had blood pressure recordings during follow-up; of these, 80% had a preexisting diagnosis of hypertension. In patients without baseline hypertension, rates of incident hypertension were 23.4, 26.6, and 28.1 per 100-person years for the lowest to highest baseline tertiles of hsCRP (P>0.2). In all participants random allocation to canakinumab did not reduce blood pressure (P>0.2) or incident hypertension during the follow-up period (hazard ratio, 0.96 [0.85–1.08], P>0.2). IL-1β inhibition with canakinumab reduces major adverse cardiovascular event rates. These analyses suggest that the mechanisms underlying this benefit are not related to changes in blood pressure or incident hypertension. Clinical Trial Registration— URL: https://clinicaltrials.gov. Unique identifier: NCT01327846.

中文翻译：

---

白细胞介素 1β 抑制对血压、高血压和残余炎症风险的影响

补充数字内容在文本中可用。虽然高血压和炎症在生理上是相互关联的，但专门针对炎症的疗法对血压的影响尚不确定。最近的 CANTOS（Canakinumab 抗炎性血栓形成结果研究）提供了测试 IL（白细胞介素）-1β 抑制是否会降低血压、预防高血压以及改变高血压与心血管事件之间关系的机会。CANTOS 将 10 061 名既往心肌梗死且 hsCRP（高敏 C 反应蛋白）≥2 mg/L 的患者随机分配至 canakinumab 50 mg、150 mg、300 mg 或安慰剂组。共有 9549 名试验参与者在随访期间进行了血压记录；其中，80% 有高血压的预先诊断。在没有基线高血压的患者中，对于 hsCRP 的最低至最高基线三分位数，高血压的发生率为 23.4、26.6 和 28.1/100 人年（P>0.2）。在所有参与者中，随机分配到 canakinumab 并没有降低随访期间的血压（P>0.2）或高血压事件（风险比，0.96 [0.85–1.08]，P>0.2）。canakinumab 抑制 IL-1β 可降低主要不良心血管事件发生率。这些分析表明，这种益处背后的机制与血压或高血压的变化无关。临床试验注册——网址：https://clinicaltrials.gov。唯一标识符：NCT01327846。在所有参与者中，随机分配到 canakinumab 并没有降低随访期间的血压（P>0.2）或高血压事件（风险比，0.96 [0.85–1.08]，P>0.2）。canakinumab 抑制 IL-1β 可降低主要不良心血管事件发生率。这些分析表明，这种益处背后的机制与血压或高血压的变化无关。临床试验注册——网址：https://clinicaltrials.gov。唯一标识符：NCT01327846。在所有参与者中，随机分配到 canakinumab 并没有降低随访期间的血压（P>0.2）或高血压事件（风险比，0.96 [0.85–1.08]，P>0.2）。canakinumab 抑制 IL-1β 可降低主要不良心血管事件发生率。这些分析表明，这种益处背后的机制与血压或高血压的变化无关。临床试验注册——网址：https://clinicaltrials.gov。唯一标识符：NCT01327846。临床试验注册——网址：https://clinicaltrials.gov。唯一标识符：NCT01327846。临床试验注册——网址：https://clinicaltrials.gov。唯一标识符：NCT01327846。